Drug intelligence / Profile preview

IA-130

Development stage: Preclinical
Lead developer: KOR Life Sciences
Modality: Small Molecules

Overview

IA-130 is a preclinical **small molecule** anticancer program from **KOR Life Sciences** directed against **DEAD-box helicase 3**. Based on the company pipeline and provided program description, the agent is intended to **inhibit DDX3 helicase activity** as a targeted antineoplastic approach, with development focused on **colorectal cancer** and **lung cancer**. No clinical-stage data, brand name, dosage form, route of administration, or manufacturer-specific commercialization details were identified from the available company pipeline information.

Targets

DDX3X (DEAD-box helicase 3 X-linked)

Beyond the preview

Go deeper on IA-130.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IA-130.

Explore the full profile